ArticleTherapeutic advances in gastroenterology2026
Comparative risk of
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antitumor necrosis factor (anti-TNF) agents are associated with an increased risk of Objectives: To compare the incidence densities (IDs) and risks of CDI and Design: Single-center retrospective cohort study. Methods: In a retrospective cohort study, we included 627 CD patients with a negative baseline Results: The cohort included 277 patients (381 person-years, PY) treated with UST and 350 patients (454 PY) treated with anti-TNF agents. CDI developed in 4 of 277 UST-treated participants (1.05/100 PY) and 9 of 350 anti-TNF-treated participants (1.98/100 PY), corresponding to an IDR of 0. Conclusion: In this real-world cohort, treatment with UST was not associated with a significantly higher risk of CDI or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.